Abstract
Despite the growing epidemic of obesity in the United States, dosing medications in such patients remains poorly studied and understood. Most recommendations are based on small independent studies, case reports, and expert opinion. Applying manufacturer kinetics and dosing recommendations in the obese patient may result in toxicity or treatment failure, leading to increased morbidity, mortality, and hospital length of stay.
Copyright © 2010 Elsevier Inc. All rights reserved.
MeSH terms
-
Aminoglycosides / administration & dosage
-
Antithrombins / administration & dosage
-
Arginine / analogs & derivatives
-
Body Mass Index*
-
Carbapenems / administration & dosage
-
Cephalosporins / administration & dosage
-
Drug Dosage Calculations*
-
Enoxaparin / administration & dosage
-
Fibrinolytic Agents / administration & dosage
-
Heparin / administration & dosage
-
Humans
-
Hypnotics and Sedatives / administration & dosage
-
Lipopeptides / administration & dosage
-
Obesity / drug therapy*
-
Obesity / metabolism
-
Oxazolidinones / administration & dosage
-
Penicillins / administration & dosage
-
Pipecolic Acids / administration & dosage
-
Protein C / administration & dosage
-
Quinolones / administration & dosage
-
Recombinant Proteins / administration & dosage
-
Safety
-
Sulfonamides
-
Vancomycin / administration & dosage
Substances
-
Aminoglycosides
-
Antithrombins
-
Carbapenems
-
Cephalosporins
-
Enoxaparin
-
Fibrinolytic Agents
-
Hypnotics and Sedatives
-
Lipopeptides
-
Oxazolidinones
-
Penicillins
-
Pipecolic Acids
-
Protein C
-
Quinolones
-
Recombinant Proteins
-
Sulfonamides
-
Vancomycin
-
Heparin
-
Arginine
-
argatroban
-
drotrecogin alfa activated